性别对FOLFIRI联合西妥昔单抗或贝伐珠单抗一线治疗RAS/BRAF野生型转移性结直肠癌疗效与安全性的影响:FIRE-3研究亚组分析
FIRE-3研究亚组分析探讨性别和原发肿瘤部位对RAS野生型mCRC一线FOLFIRI联合西妥昔单抗或贝伐珠单抗疗效的影响。352例RAS野生型患者中男性249例、女性103例。探索性分析提示西妥昔单抗联合FOLFIRI的疗效与性别及原发肿瘤部位相关。
要点
- 男性左侧RAS/BRAF野生型肿瘤患者西妥昔单抗组ORR和OS显著获益。
- 女性右侧原发肿瘤患者西妥昔单抗组PFS显著更差(HR 4.95)。
- 贝伐珠单抗组女性≥3级中性粒细胞减少发生率高于男性(30.6% vs 18.3%)。
核心结论
- FIRE-3研究探索性分析提示,RAS野生型mCRC中FOLFIRI联合西妥昔单抗的疗效与性别和原发肿瘤部位相关。
研究设计与样本
- 随机FIRE-3研究比较FOLFIRI联合西妥昔单抗与FOLFIRI联合贝伐珠单抗一线治疗RAS野生型mCRC。
- 本分析纳入352例RAS野生型患者,其中男性249例(71%),女性103例(29%)。
主要发现
- 男性左侧RAS/BRAF野生型肿瘤患者中,西妥昔单抗组ORR(OR 1.15;P=0.035)和OS(0.66;P=0.010)显著获益。
- 男性右侧肿瘤患者中,西妥昔单抗组ORR改善(OR 2.92),PFS和OS无显著影响。
- 女性左侧RAS/BRAF野生型肿瘤患者中,西妥昔单抗组与贝伐珠单抗组ORR相当(OR 1.05;P>0.999),西妥昔单抗组OS有数值获益(HR 0.78;P=0.385)。
- 女性右侧肿瘤患者中,西妥昔单抗组ORR(OR 0.44;P=0.617)、PFS(HR 4.95;P=0.005)和OS(HR 2.58;P=0.080)显示不利影响。
- 贝伐珠单抗组女性≥3级中性粒细胞减少发生率高于男性(30.6% vs 18.3%;P=0.063),其他≥3级不良事件无显著性别差异。
临床怎么用
- 对RAS/BRAF野生型mCRC选择一线靶向治疗时,可结合性别和原发肿瘤部位个体化考虑。
局限性
- 本分析为FIRE-3研究的探索性亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical trials in metastatic colorectal cancer (mCRC) are usually conducted irrespectively of sex. However, differences relating to safety and efficacy in the treatment of mCRC between male and female patients are of growing interest. METHODS: The randomized FIRE-3 study compared first-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) plus cetuximab to FOLFIRI plus bevacizumab in patients with RAS wildtype (RAS WT) mCRC. The present analysis focusses on the impact of sex and primary tumor (PT) sidedness on outcome parameters. RESULTS: Of 352 patients with RAS WT tumors, 249 (71 %) were male and 103 (29 %) female. In male patients with left-sided RAS/BRAF WT tumors, a significant benefit from cetuximab was noted with regard to ORR (OR 1.15; P = 0.035) and OS (0.66; P = 0.010), while in right-sided patients cetuximab improved ORR (OR 2.92) and had no significant effect on PFS or OS. In female patients with left-sided, RAS/BRAF WT PT, a comparable effect of cetuximab versus bevacizumab was observed with regard to ORR (OR 1.05; P > 0.999), while a numerical OS benefit was noted in the cetuximab-arm (HR 0.78; P = 0.385). By contrast, in female patients with right-sided PT, a clearly detrimental effect of cetuximab-based therapy was observed for ORR (OR 0.44; P = 0.617), PFS (HR 4.95; P = 0.005), and OS (HR 2.58; P = 0.080). In the bevacizumab arm, neutropenia grade ≥ 3 was more frequent in female versus male patients (30.6 % versus 18.3 %; P = 0.063). Otherwise, there was no significant difference of grade ≥ 3 adverse events between male and female patients. CONCLUSIONS: The exploratory analysis of FIRE-3 suggests that the efficacy of cetuximab combined with FOLFIRI in RAS wild-type mCRC is related to sex and primary tumor sidedness. The results support the inclusion of patient sex into the design of future trials.
引用
- Heinrich K, Stintzing S, Weikersthal LFV, et al. Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial. Eur J Cancer. 2025. PMID: 41319450. doi:10.1016/j.ejca.2025.116133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。